Business Context and Reporting Period
This Form 8-K is filed by Frequency Therapeutics, Inc. (not Korro Bio, Inc.) on August 10, 2023. The report announces financial results and operational updates for the quarter ended June 30, 2023. The company is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Global Select Market under the symbol FREQ.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the referenced press release for specific financial figures.
Material Changes
The filing text does not contain specific quantitative comparisons to prior periods. It indicates that operational updates were provided alongside the financial results, but the nature of these changes is not detailed in the 8-K body.
Guidance, Outlook, and Risks
The company provided operational updates in the associated press release. The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 liabilities of the Exchange Act nor incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name is Frequency Therapeutics, Inc., as the input metadata incorrectly listed "Korro Bio, Inc."
- Locate and review Exhibit 99.1 (Press Release) to obtain actual revenue, cash burn, and liquidity figures, as they are absent from the 8-K text.
- Confirm the specific details of the "operational updates" mentioned in the press release to assess material changes.
- Note that the financial data in this filing is not deemed "filed" for legal liability purposes under Section 18 of the Exchange Act.